Precigen (PGEN) Competitors

Precigen (NASDAQ:PGEN) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.

Which has more risk & volatility, PGEN or CLLS?

Precigen has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.1, indicating that its share price is 210% more volatile than the S&P 500.

Does the MarketBeat Community favor PGEN or CLLS?

Precigen received 27 more outperform votes than Cellectis when rated by MarketBeat users. Likewise, 67.29% of users gave Precigen an outperform vote while only 65.75% of users gave Cellectis an outperform vote.

Company	Underperform	Outperform
Precigen	Outperform Votes 434 67.29%	Underperform Votes 211 32.71%
Cellectis	Outperform Votes 407 65.75%	Underperform Votes 212 34.25%

Does the media favor PGEN or CLLS?

In the previous week, Precigen had 8 more articles in the media than Cellectis. MarketBeat recorded 12 mentions for Precigen and 4 mentions for Cellectis. Cellectis' average media sentiment score of 0.72 beat Precigen's score of 0.26 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend PGEN or CLLS?

Precigen currently has a consensus target price of $7.00, indicating a potential upside of 753.55%. Cellectis has a consensus target price of $7.00, indicating a potential upside of 274.33%. Given Precigen's higher probable upside, equities research analysts plainly believe Precigen is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Cellectis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of PGEN or CLLS?

33.5% of Precigen shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 44.9% of Precigen shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is PGEN or CLLS more profitable?

Cellectis has a net margin of -234.39% compared to Precigen's net margin of -3,521.68%. Cellectis' return on equity of -74.55% beat Precigen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-3,521.68%	-112.05%	-80.73%
Cellectis	-234.39%	-74.55%	-22.65%

Which has better earnings & valuation, PGEN or CLLS?

Precigen has higher earnings, but lower revenue than Cellectis. Precigen is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$4.39M	47.23	-$95.90M	-$0.55	-1.49
Cellectis	$9.19M	11.31	-$101.06M	-$1.30	-1.44

Summary

Precigen and Cellectis tied by winning 9 of the 18 factors compared between the two stocks.